(Reuters) – Moderna Inc is slowing enrollment slightly in its large clinical trial for coronavirus vaccine candidate to ensure it has sufficient representation of minorities most at risk for the disease, CNBC reported, citing the company’s chief executive.
Shares of the company fell 7% in morning trading.
“I would rather we have higher diverse participants and take one extra week,” CEO Stephane Bancel told CNBC.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
